These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12912944)

  • 21. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
    Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H
    J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.
    Borbulevych OY; Baxter TK; Yu Z; Restifo NP; Baker BM
    J Immunol; 2005 Apr; 174(8):4812-20. PubMed ID: 15814707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
    Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA
    J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
    Ginsberg BA; Gallardo HF; Rasalan TS; Adamow M; Mu Z; Tandon S; Bewkes BB; Roman RA; Chapman PB; Schwartz GK; Carvajal RD; Panageas KS; Terzulli SL; Houghton AN; Yuan JD; Wolchok JD
    Clin Cancer Res; 2010 Aug; 16(15):4057-65. PubMed ID: 20647477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells.
    Prabakaran I; Menon C; Xu S; Gómez-Yafal A; Czerniecki BJ; Fraker DL
    Ann Surg Oncol; 2002 May; 9(4):411-8. PubMed ID: 11986195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
    Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
    J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.
    Chiong B; Wong R; Lee P; Delto J; Scotland R; Lau R; Weber J
    J Immunother; 2004; 27(5):368-79. PubMed ID: 15314545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional characterization of CTL against gp100 altered peptide ligands.
    Dionne SO; Smith MH; Marincola FM; Lake DF
    Cancer Immunol Immunother; 2003 Apr; 52(4):199-206. PubMed ID: 12669244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
    Pullarkat V; Lee PP; Scotland R; Rubio V; Groshen S; Gee C; Lau R; Snively J; Sian S; Woulfe SL; Wolfe RA; Weber JS
    Clin Cancer Res; 2003 Apr; 9(4):1301-12. PubMed ID: 12684398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
    Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE
    J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
    Powell DJ; Rosenberg SA
    J Immunother; 2004; 27(1):36-47. PubMed ID: 14676632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
    Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
    Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
    Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
    Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.
    Spaner DE; Astsaturov I; Vogel T; Petrella T; Elias I; Burdett-Radoux S; Verma S; Iscoe N; Hamilton P; Berinstein NL
    Cancer; 2006 Feb; 106(4):890-9. PubMed ID: 16404742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
    Overwijk WW; Tsung A; Irvine KR; Parkhurst MR; Goletz TJ; Tsung K; Carroll MW; Liu C; Moss B; Rosenberg SA; Restifo NP
    J Exp Med; 1998 Jul; 188(2):277-86. PubMed ID: 9670040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
    Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
    J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.